STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4%
Fri, 5 Feb

STRIDES PHARMA SCIENCE has announced its results for the quarter ended December 2020. Here is a detailed performance review of the same:

STRIDES PHARMA SCIENCE Quarterly Financials

No. of Mths
Qtr. Ending
3
Dec-19*
3
Sep-20*
3
Dec-20*
QoQ ChangeYoY Change
Net SalesRs m7,3247,9368,3204.8%13.6%
Other incomeRs m1221291322.6%8.0%
TurnoverRs m7,4478,0648,4524.8%13.5%
ExpensesRs m5,5026,3156,7146.3%22.0%
Gross profitRs m1,9791,7521,468-16.2%-25.8%
DepreciationRs m435528525-0.5%20.8%
InterestRs m396369347-5.9%-12.5%
Profit before taxRs m1,270984728-26.0%-42.6%
TaxRs m1136110876.5%-4.7%
Profit after taxRs m1,157923621-32.8%-46.4%
Gross profit margin%27.022.117.6
Effective tax rate%8.96.214.8
Net profit margin%15.511.47.3
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 13.6% on a year-on-year (YoY) basis. The expenses were up by 22.0% YoY during the same period.
  • The company's operating profit declined by 25.8% YoY during the quarter. Consequently, operating profit margins witnessed a decline and stood at 17.6% in 3QFY21 as against 27.0% in 3QFY20.
  • Depreciation charges increased by 20.8% and finance costs declined by 12.5% YoY, respectively.
  • Other income increased by 8.0% YoY during the quarter.
  • Net profit for the quarter declined by 46.4% YoY. Net profit margins during the quarter declined from 15.5% in 3QFY20 to 7.3% in 3QFY21.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 4.8% on a quarter-on-quarter (QoQ) basis. The expenses were up by 6.3% QoQ during the same period.
  • The company's operating profit declined by 16.2% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 17.6% in 3QFY21 as against 22.1% in 2QFY20.
  • Net profit for the quarter declined by 32.8% QoQ, while net profit margins declined from 11.4% in 2QFY20 to 7.3% in 3QFY21.

To see how STRIDES PHARMA SCIENCE has performed over the last eight quarters,please visit here.

JUST IN: Limited-Time Access to Full Transcript of Our Urgent Broadcast on India's Revival

STRIDES PHARMA SCIENCE Share Price Performance

Over the last one year, STRIDES PHARMA SCIENCE share price has moved up from Rs 493.6 to Rs 873.6, registering a Gain of Rs 380.0 or around 77.0%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 21,735.0 (up 0.5%). Over the last one year it has moved up from 13,946.5 to 21,735.0, a gain of 7,788 points (up 55.8%).

Overall, the S&P BSE SENSEX is up 27.4% over the year.

Current Valuations

At the current price of Rs 873.6, the price to earnings (P/E) ratio of STRIDES PHARMA SCIENCE stands at 45.5 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 2.1 times.

Equitymaster requests your view! Post a comment on "STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4%". Click here!

  

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Apr 16, 2021 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS